These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 27266051)

  • 1. [The Catting-edge of Medicine; Anti-viral therapies for chronic hepatitis C].
    Takehara T
    Nihon Naika Gakkai Zasshi; 2016 Jan; 105(1):112-8. PubMed ID: 27266051
    [No Abstract]   [Full Text] [Related]  

  • 2. [Treatment efficacy and safety in elderly genotype 1b chronic hepatitis C patients with high viral load].
    Nishikawa H
    Nihon Rinsho; 2015 Dec; 73 Suppl 9():209-13. PubMed ID: 26845932
    [No Abstract]   [Full Text] [Related]  

  • 3. Are we nearing the end in the fight against hepatitis C?
    Chua JV; Kottilil S
    Expert Rev Gastroenterol Hepatol; 2017 Jun; 11(6):499-500. PubMed ID: 28335650
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical Laboratory Testing in the Era of Directly Acting Antiviral Therapies for Hepatitis C.
    Wilson EM; Rosenthal ES; Kattakuzhy S; Tang L; Kottilil S
    Clin Microbiol Rev; 2017 Jan; 30(1):23-42. PubMed ID: 27795306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is there a role for ribavirin in the era of hepatitis C virus direct-acting antivirals?
    Feld JJ
    Gastroenterology; 2012 May; 142(6):1356-9. PubMed ID: 22537443
    [No Abstract]   [Full Text] [Related]  

  • 6. [Conclusions].
    Pineda JA
    Enferm Infecc Microbiol Clin; 2013 Jul; 31 Suppl 3():49-50. PubMed ID: 24063903
    [No Abstract]   [Full Text] [Related]  

  • 7. Aspects of the future of therapy for patients infected with a high viral load and interferon-resistant subtype of HCV.
    Matsumoto A; Kiyosawa K
    J Gastroenterol; 2002; 37(9):766-8. PubMed ID: 12375156
    [No Abstract]   [Full Text] [Related]  

  • 8. Addressing the Challenges of Hepatitis C Virus Resistance and Treatment Failure.
    Colpitts CC; Baumert TF
    Viruses; 2016 Aug; 8(8):. PubMed ID: 27537906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals.
    Ahmed A; Felmlee DJ
    Viruses; 2015 Dec; 7(12):6716-29. PubMed ID: 26694454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is hepatitis virus resistance to antiviral drugs a threat?
    Pawlotsky JM
    Gastroenterology; 2012 May; 142(6):1369-72. PubMed ID: 22537445
    [No Abstract]   [Full Text] [Related]  

  • 11. Rapid suppression of hepatitis C viremia induced by intravenous silibinin plus ribavirin.
    Biermer M; Berg T
    Gastroenterology; 2009 Jul; 137(1):390-1. PubMed ID: 19486953
    [No Abstract]   [Full Text] [Related]  

  • 12. Combination therapy with telaprevir and pegylated interferon suppresses both wild-type and resistant hepatitis C virus.
    Lang L
    Gastroenterology; 2007 Jan; 132(1):5-6. PubMed ID: 17241851
    [No Abstract]   [Full Text] [Related]  

  • 13. Geno2pheno[HCV] - A Web-based Interpretation System to Support Hepatitis C Treatment Decisions in the Era of Direct-Acting Antiviral Agents.
    Kalaghatgi P; Sikorski AM; Knops E; Rupp D; Sierra S; Heger E; Neumann-Fraune M; Beggel B; Walker A; Timm J; Walter H; Obermeier M; Kaiser R; Bartenschlager R; Lengauer T
    PLoS One; 2016; 11(5):e0155869. PubMed ID: 27196673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Direct-acting antiviral treatment of chronic hepatitis C infection].
    Grüner N; Gerbes A
    MMW Fortschr Med; 2015 Apr; 157(8):57-60. PubMed ID: 26012687
    [No Abstract]   [Full Text] [Related]  

  • 15. Hepatitis C Virus and Antiviral Drug Resistance.
    Kim S; Han KH; Ahn SH
    Gut Liver; 2016 Nov; 10(6):890-895. PubMed ID: 27784846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutagenic effects of ribavirin in vivo.
    Perelson AS; Ribeiro RM
    J Hepatol; 2005 Oct; 43(4):553-5. PubMed ID: 16099528
    [No Abstract]   [Full Text] [Related]  

  • 17. [New combination attains a response rate of 90].
    Warpakowski A
    MMW Fortschr Med; 2015 Sep; 157(15):71. PubMed ID: 26349741
    [No Abstract]   [Full Text] [Related]  

  • 18. [HCV protease inhibitors and drug resistance].
    Pawłowska M; Olczak A
    Przegl Epidemiol; 2012; 66(1):55-7. PubMed ID: 22708299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiviral resistance and direct-acting antiviral agents for HCV.
    Aloia AL; Locarnini S; Beard MR
    Antivir Ther; 2012; 17(6 Pt B):1147-62. PubMed ID: 23188771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis C virus drug resistance: implications for clinical management.
    Wyles DL
    Infect Dis Clin North Am; 2012 Dec; 26(4):967-78. PubMed ID: 23083827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.